Call Options

16 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$64.0 - $116.06 $6,400 - $11,606
-100 Reduced 0.08%
127,500 $1.94 Billion
Q2 2024

Aug 14, 2024

BUY
$110.31 - $140.45 $14.1 Million - $17.9 Million
127,600 New
127,600 $1.95 Billion
Q4 2022

Feb 14, 2023

SELL
$84.98 - $122.67 $42,490 - $61,335
-500 Reduced 3.76%
12,800 $133,000
Q3 2022

Nov 14, 2022

SELL
$76.35 - $94.18 $30,539 - $37,672
-400 Reduced 2.92%
13,300 $35,000
Q2 2022

Aug 12, 2022

BUY
$67.99 - $132.89 $652,704 - $1.28 Million
9,600 Added 234.15%
13,700 $41,000
Q1 2022

May 12, 2022

SELL
$94.08 - $130.2 $5.17 Million - $7.16 Million
-55,000 Reduced 93.06%
4,100 $387,000
Q4 2021

Feb 14, 2022

BUY
$129.87 - $162.82 $259,740 - $325,640
2,000 Added 3.5%
59,100 $9.16 Million
Q3 2021

Nov 10, 2021

SELL
$106.71 - $143.18 $10.6 Million - $14.2 Million
-99,100 Reduced 63.44%
57,100 $9.92 Million
Q2 2021

Aug 11, 2021

BUY
$80.99 - $107.93 $8.09 Million - $10.8 Million
99,900 Added 177.44%
156,200 $4.61 Million
Q1 2021

May 14, 2021

SELL
$84.79 - $104.74 $1.05 Million - $1.3 Million
-12,400 Reduced 18.05%
56,300 $2.96 Million
Q4 2020

Feb 16, 2021

BUY
$78.0 - $104.5 $429,000 - $574,750
5,500 Added 8.7%
68,700 $6.22 Million
Q3 2020

Nov 13, 2020

SELL
$95.51 - $112.95 $76,408 - $90,360
-800 Reduced 1.25%
63,200 $8.8 Million
Q2 2020

Aug 10, 2020

BUY
$62.68 - $105.34 $3.31 Million - $5.56 Million
52,800 Added 471.43%
64,000 $8.91 Million
Q1 2020

May 08, 2020

SELL
$47.79 - $75.63 $14,337 - $22,689
-300 Reduced 2.61%
11,200 $1.33 Million
Q4 2019

Feb 11, 2020

SELL
$36.62 - $57.29 $69,578 - $108,851
-1,900 Reduced 14.18%
11,500 $892,000
Q3 2019

Nov 12, 2019

BUY
$35.53 - $43.8 $476,102 - $586,920
13,400 New
13,400 $334,000

Others Institutions Holding DXCM

About DEXCOM INC


  • Ticker DXCM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 386,257,984
  • Market Cap $29.5B
  • Description
  • DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM ...
More about DXCM
Track This Portfolio

Track Hap Trading, LLC Portfolio

Follow Hap Trading, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hap Trading, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Hap Trading, LLC with notifications on news.